IMGN - ImmunoGen, Inc.
6.17 0.00 (0.00%)
After hours: 4:46PM EDT
| Previous Close | 6.42 |
| Open | 6.35 |
| Bid | 6.18 x 100 |
| Ask | 6.50 x 3200 |
| Day's Range | 6.08 - 6.47 |
| 52 Week Range | 1.51 - 8.84 |
| Volume | 2,426,799 |
| Avg. Volume | 3,795,341 |
| Market Cap | 642.28M |
| Beta | 2.38 |
| PE Ratio (TTM) | -5.07 |
| EPS (TTM) | -1.22 |
| Earnings Date | Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.17 |
- Zacks•9 hours ago
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
- Zacks•2 days ago
ImmunoGen to Push Leukemia Candidate into Phase I Trial
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
- Business Wire•3 days ago
ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the U.S. Food and Drug Administration has completed the safety review of its investigational new drug application for IMGN632 in patients with CD123-positive hematological malignancies, including acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm .
- Business Wire•8 days ago
ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ImmunoGen, Inc. today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $6.50 per share.
- Capital Cube•9 days ago
ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : October 10, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ImmunoGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
- MarketWatch•13 days ago
Immunogen secondary offering priced below Friday's closing price
Immunogen Inc. priced its secondary offering below the price of the close of shares on Friday, according to a filing with the Securities and Exchange Commission. The biotech company priced 14.5 million ...
- Business Wire•14 days ago
ImmunoGen Announces Pricing of Public Offering of Common Stock
ImmunoGen, Inc. today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.50 per share, before underwriting discounts.
- 24/7 Wall St.•14 days ago
Why ImmunoGen’s Secondary Makes Sense
ImmunoGen saw its shares make a sharp turn downward on Thursday morning after the stock has seen an incredible year of trading so far.
- ACCESSWIRE•14 days ago
Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and ImmunoGen
NEW YORK, NY / ACCESSWIRE / October 5, 2017 / U.S. markets continue to reach new record highs in the fourth quarter on strong economic data. The Dow Jones Industrial Average gained 0.09 percent to close ...
- MarketWatch•15 days ago
Immunogen shares fall after secondary share offering announced
Immunogen Inc. shares fell in the extended session Wednesday after the biotech company announced a secondary offering of shares. Immunogen shares fell 10% to $7.05 after hours. The company said it plans ...
- Business Wire•15 days ago
ImmunoGen Announces Proposed Public Offering of Common Stock
ImmunoGen, Inc. today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common stock in an underwritten public offering.
- Simply Wall St.•16 days ago
Should You Be Holding ImmunoGen Inc (IMGN) Right Now?
If you are a shareholder in ImmunoGen Inc’s (NASDAQ:IMGN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
- Motley Fool•19 days ago
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
Two hot biotech stocks with exciting cancer drugs. But which is the better pick in a head-to-head match-up?
- Capital Cube•24 days ago
ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : September 25, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives ImmunoGen, Inc. a score of 13. Our analysis is based on comparing ImmunoGen, Inc. with the following peers – Seattle Genetics, Inc., Endocyte, Inc., Amgen Inc., Dare Bioscience, Inc., Pfizer Inc., Roche Holding Ltd Genusssch., Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR and Novartis ... Read more (Read more...)
Capital Cube•27 days agoImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for ImmunoGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
- Simply Wall St.•last month
ImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying
If you are a shareholder in ImmunoGen Inc’s (NASDAQ:IMGN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
- Motley Fool•last month
Is ImmunoGen Running Out of Steam, or Taking a Breather?
What goes up must come down. But the question for this high-flying biotech stock is: For how long?
- Motley Fool•last month
Why Shares of ImmunoGen, Inc. Sank Today
A little dilution has investors worried.
- Market Realist•last month
Behind Jazz’s Strategic Collaboration with ImmunoGen
In August 2017, Jazz Pharmaceuticals (JAZZ) and ImmunoGen (IMGN) entered into a strategic collaboration and option agreement.
- Business Wire•last month
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the following presentations by
- Zacks•last month
Bull of the Day: Jazz Pharmaceuticals (JAZZ)
Bull of the Day: Jazz Pharmaceuticals (JAZZ)
- Business Wire•2 months ago
ImmunoGen Announces Agreements to Exchange $76.4 Million of Its 4.50% Convertible Senior Notes Due 2021 for Common Stock
ImmunoGen, Inc. today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
- Capital Cube•2 months ago
ETFs with exposure to ImmunoGen, Inc. : August 31, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ImmunoGen, Inc. Here are 5 ETFs with the largest exposure to IMGN-US. Comparing the performance and risk of ImmunoGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Forbes•2 months ago
Biotechs On The Move
Our top charts to watch this week feature three biotechs and one online insurance stock moving on strong technicals and news.
